| Literature DB >> 18976449 |
Michael F Leitzmann1, Steven C Moore, Tricia M Peters, James V Lacey, Arthur Schatzkin, Catherine Schairer, Louise A Brinton, Demetrius Albanes.
Abstract
INTRODUCTION: To prospectively examine the relation of total, vigorous and non-vigorous physical activity to postmenopausal breast cancer risk.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18976449 PMCID: PMC2614500 DOI: 10.1186/bcr2190
Source DB: PubMed Journal: Breast Cancer Res ISSN: 1465-5411 Impact factor: 6.466
Baseline characteristics according to quintiles of total physical activity in 32,269 women in the Breast Cancer Detection Demonstration Project (BCDDP)*
| 1 | 2 | 3 | 4 | 5 | |
| Participants (n) | 6453 | 6454 | 6441 | 6472 | 6449 |
| Age (years) | 61.7 | 61.1 | 61.3 | 60.8 | 61.0 |
| MET-hours/week (range) † | 105 to 244 | 245 to 297 | 298 to 339 | 340 to 394 | 395 to 721 |
| Vigorous physical activity (hours/week) | 0.9 | 3.6 | 5.4 | 10.3 | 22.7 |
| Non-vigorous physical activity (hours/week) | 14.8 | 32.4 | 46.5 | 54.5 | 59.7 |
| Body mass index (kg/m2) | 25.4 | 25.0 | 24.9 | 24.7 | 24.6 |
| Height (inches) | 64.3 | 64.2 | 64.2 | 64.2 | 64.1 |
| Ever smoked cigarettes (%) | 46.9 | 44.6 | 43.4 | 42.1 | 40.7 |
| Education (% more than high school) | 55.0 | 50.0 | 46.8 | 46.1 | 42.0 |
| Age at first birth (years) ‡ | 24.0 | 23.9 | 23.8 | 23.9 | 23.5 |
| Parity (number of births) ‡ | 2.8 | 2.8 | 2.9 | 2.9 | 3.0 |
| Age at menarche (years) | 12.7 | 12.7 | 12.8 | 12.8 | 12.9 |
| Age at menopause (years) | 50.4 | 50.3 | 50.2 | 50.4 | 50.3 |
| History of oral contraceptive use (%) | 33.8 | 33.2 | 33.4 | 32.8 | 31.1 |
| Current menopausal hormone therapy (%) | 55.3 | 54.7 | 55.8 | 55.7 | 54.1 |
| Family history of breast cancer (%) ¶ | 34.0 | 35.1 | 34.1 | 34.4 | 33.6 |
| History of benign breast disease (%) § | 55.5 | 56.0 | 55.4 | 55.6 | 55.2 |
| Total energy intake (kcal/day) | 1252 | 1256 | 1266 | 1271 | 1277 |
| Dietary fat intake (g/day) || | 46.9 | 46.5 | 46.3 | 46.0 | 45.9 |
| Alcohol intake (g/day) | 4.5 | 4.4 | 4.1 | 4.0 | 3.6 |
* All values (except age and range of MET-hours/week) are directly standardised to the age distribution of the cohort at study baseline.
† MET = metabolic equivalent task. The MET value is the caloric need per kilogram of body weight per hour of activity divided by the caloric need per kilogram of body weight per hour at rest.
‡ Among parous women only.
¶Family history of breast cancer includes first- and second-degree relatives with a history breast cancer.
§The BCDDP Follow-up Study includes a disproportionate number of women with benign breast disease due to the design of the original BCDDP.
||Adjusted for total energy intake.
Relative risk of postmenopausal breast cancer in relation to total physical activity among US women in the Breast Cancer Detection Demonstration Project (BCDDP; 1987 to 1998)*
| 1 | 2 | 3 | 4 | 5 | ||
| MET-hours/week (range) | 105 to 244 | 245 to 297 | 298 to 339 | 340 to 394 | 395 to 721 | |
| Cases | 320 | 300 | 308 | 312 | 266 | |
| Person-years | 52,858 | 53,967 | 54,019 | 54,487 | 54,461 | |
| Age-adjusted RR (95% CI) | 1.0 | 0.92 (0.79 to 1.08) | 0.94 (0.81 to 1.10) | 0.95 (0.82 to 1.12) | 0.81 (0.69 to 0.95) | 0.03 |
| Multivariate RR † (95% CI) | 1.0 | 0.92 (0.79 to 1.08) | 0.97 (0.83 to 1.14) | 0.98 (0.84 to 1.15) | 0.86 (0.73 to 1.01) | 0.15 |
| Multivariate RR ‡ (95% CI) | 1.0 | 0.93 (0.80 to 1.09) | 0.98 (0.84 to 1.14) | 1.00 (0.85 to 1.16) | 0.87 (0.74 to 1.02) | 0.21 |
* CI = confidence interval; MET = metabolic equivalent task; RR = relative risk.
† The multivariate model included the following: age at baseline (continuous), family history of breast cancer (any first- or second-degree relative; yes, no or unknown), history of benign breast disease (any benign breast disease prior to study baseline, including during the screening stages; yes or, no), breast cancer screening history (women who had undergone a breast biopsy as part of the BCDDP screening but lacked evidence of malignant disease, women who were recommended for surgical consultation as part of the BCDDP but for whom the procedure was not performed, or women who represented a random sample of BCDDP participants who had no surgery or recommendation for surgical consultation during BCDDP screening), height (continuous), age at menarche (≤ 11, 12, 13 or 14+ years of age), age at menopause (age at which menstrual period stopped for at least three continuous months; <47 or 47+ years of age), age at first live birth (continuous), history of oral contraceptive use (yes or no), menopausal hormone therapy (ever or never), education attainment (less than or equal to high school, or greater than high school), cigarette smoking (ever or never), and intakes of energy-adjusted dietary fat (continuous) and alcohol (continuous).
‡ Also controlled for body mass index (continuous).
Relative risk of postmenopausal breast cancer in relation to vigorous and non-vigorous physical activity among US women in the Breast Cancer Detection Demonstration Project (BCDDP: 1987 to 1998)*
| 1 | 2 | 3 | 4 | 5 | ||
| MET-hours/week | 0 | 0.1 to 48.9 | 49.0 to 70.0 | 70.1 to 126.0 | 126.1 to 588.0 | |
| Cases | 614 | 236 | 234 | 218 | 204 | |
| Person-years | 101,276 | 40,772 | 44,949 | 41,072 | 41,772 | |
| Age-adjusted RR (95% CI) | 1.0 | 1.00 (0.86 to 1.17) | 0.89 (0.76 to 1.03) | 0.90 (0.77 to 1.06) | 0.82 (0.70 to 0.96) | 0.008 |
| Multivariate RR † §(95% CI) | 1.0 | 0.98 (0.84 to 1.14) | 0.88 (0.76 to 1.03) | 0.91 (0.78 to 1.07) | 0.86 (0.73 to 1.01) | 0.06 |
| Multivariate RR ‡ §(95% CI) | 1.0 | 0.98 (0.85 to 1.15) | 0.89 (0.76 to 1.04) | 0.92 (0.79 to 1.08) | 0.87 (0.74 to 1.02) | 0.08 |
| MET hours per week | 0 to 84.0 | 84.1 to 140.0 | 140.1 to 188.0 | 188.1 to 229.0 | 229.1 to 504.0 | |
| Cases | 317 | 314 | 283 | 287 | 305 | |
| Person-years | 53,660 | 56,791 | 52,224 | 53,001 | 54,116 | |
| Age-adjusted RR (95% CI) | 1.0 | 0.94 (0.80 to 1.09) | 0.91 (0.78 to 1.07) | 0.91 (0.77 to 1.06) | 0.95 (0.81 to 1.11) | 0.48 |
| Multivariate RR † || (95% CI) | 1.0 | 0.99 (0.84 to 1.16) | 0.98 (0.83 to 1.16) | 0.97 (0.82 to 1.14) | 1.01 (0.86 to 1.18) | 0.96 |
| Multivariate RR ‡ || (95% CI) | 1.0 | 0.99 (0.84 to 1.16) | 0.99 (0.84 to 1.16) | 0.97 (0.82 to 1.14) | 1.02 (0.87 to 1.19) | 0.86 |
* CI = confidence interval; MET = metabolic equivalent task; RR = relative risk.
† The multivariate model included the following: age at baseline (continuous), family history of breast cancer (any first- or second-degree relative; yes, no or unknown), history of benign breast disease (any benign breast disease prior to study baseline, including during the screening stages; yes or no), breast cancer screening history (women who had undergone a breast biopsy as part of the BCDDP screening but lacked evidence of malignant disease, women who were recommended for surgical consultation as part of the BCDDP but for whom the procedure was not performed, or women who represented a random sample of BCDDP participants who had no surgery or recommendation for surgical consultation during BCDDP screening), height (continuous), age at menarche (≤ 11, 12, 13 or 14+ years of age), age at menopause (age at which menstrual period stopped for at least three continuous months; <47 or 47+ years of age), age at first live birth (continuous), history of oral contraceptive use (yes or no), menopausal hormone therapy (ever or never), education attainment (less than or equal to high school or greater than high school), cigarette smoking (ever or never), and intakes of energy-adjusted dietary fat (continuous) and alcohol (continuous).
‡ Also controlled for body mass index (continuous).
§Also controlled for non-vigorous physical activity (quintiles).
||Also controlled for vigorous activity (5 categories).
Relative risk of postmenopausal breast cancer in relation to total, vigorous and non-vigorous physical activity in subgroups defined by body mass index among US women in the Breast Cancer Detection Demonstration Project (BCDDP; 1987 to 1998)*
| < 25.0 kg/m2 | 876 | 1.0 | 0.88 (0.71 to 1.08) | 0.92 (0.75 to 1.12) | 0.91 (0.74 to 1.11) | 0.76 (0.61 to 0.94) | 0.03 | |
| ≥ 25.0 kg/m2 | 630 | 1.0 | 1.01 (0.79 to 1.29) | 1.07 (0.84 to 1.37) | 1.12 (0.88 to 1.43) | 1.06 (0.82 to 1.36) | 0.48 | 0.19 |
| < 25.0 kg/m2 | 876 | 1.0 | 0.87 (0.72 to 1.07) | 0.81 (0.67 to 0.99) | 0.90 (0.73 to 1.10) | 0.68 (0.54 to 0.85) | 0.002 | |
| ≥ 25.0 kg/m2 | 630 | 1.0 | 1.15 (0.91 to 1.46) | 1.00 (0.79 to 1.27) | 0.93 (0.72 to 1.21) | 1.18 (0.93 to 1.49) | 0.33 | 0.008 |
| < 25.0 kg/m2 | 876 | 1.0 | 0.97 (0.79 to 1.20) | 1.05 (0.85 to 1.31) | 0.97 (0.78 to 1.20) | 0.98 (0.79 to 1.21) | 0.85 | |
| ≥ 25.0 kg/m2 | 630 | 1.0 | 1.01 (0.79 to 1.28) | 0.90 (0.69 to 1.16) | 0.98 (0.77 to 1.27) | 1.09 (0.85 to 1.39) | 0.59 | 0.47 |
CI = confidence interval; RR = relative risk. The multivariate model included the following: age at baseline (continuous), family history of breast cancer (any first- or second-degree relative; yes, no or unknown), history of benign breast disease (any benign breast disease prior to study baseline, including during the screening stages; yes or no), breast cancer screening history (women who had undergone a breast biopsy as part of the BCDDP screening but lacked evidence of malignant disease, women who were recommended for surgical consultation as part of the BCDDP but for whom the procedure was not performed, or women who represented a random sample of BCDDP participants who had no surgery or recommendation for surgical consultation during BCDDP screening), height (continuous), age at menarche (≤ 11, 12, 13 or 14+ years of age), age at menopause (age at which menstrual period stopped for at least three continuous months; <47 or 47+ years of age), age at first live birth (continuous), history of oral contraceptive use (yes or no), menopausal hormone therapy (ever or never), education attainment (less than or equal to high school or greater than high school), cigarette smoking (ever or never), and intakes of energy-adjusted dietary fat (continuous) and alcohol (continuous). Within each stratum, the group with lowest vigorous physical activity served as the reference group.
† Body mass index is the weight in kilograms divided by height in metres squared.
Relative risk of oestrogen receptor positive (ER+) breast cancer and oestrogen receptor negative (ER-) breast cancer in relation to vigorous physical activity among US women in the Breast Cancer Detection Demonstration Project (BCDDP; 1987 to 1998)*
| ER+ | 706 | 1.0 | 0.94 | 0.93 | 0.93 | 0.91 (0.72 to 1.15) | 0.42 |
| PR+ | 588 | 1.0 | 1.13 | 0.97 | 1.03 | 0.93 (0.72 to 1.22) | 0.54 |
| ER+/PR+ | 555 | 1.0 | 1.08 | 0.97 | 1.02 | 0.93 (0.71 to 1.23) | 0.61 |
| ER+/PR- | 115 | 1.0 | 2.40 | 0.89 | 0.97 | 0.49 (0.10 to 2.32) | 0.22 |
| ER- | 161 | 1.0 | 1.36 | 0.79 | 1.02 | 0.74 (0.44 to 1.27) | 0.22 |
| PR- | 248 | 1.0 | 0.77 | 0.74 | 0.80 | 0.77 (0.52 to 1.15) | 0.23 |
| ER-/PR+ | 29 | 1.0 | 0.55 | 0.60 | 0.56 | 0.81 (0.46 to 1.41) | 0.43 |
| ER-/PR- | 126 | 1.0 | 1.02 | 0.80 | 1.06 | 0.76 (0.42 to 1.35) | 0.43 |
| ER+, BMI < 25.0 kg/m2 | 417 | 1.0 | 0.79 | 0.87 | 0.95 | 0.75 (0.54 to 1.03) | 0.15 |
| ER+, BMI ≥ 25.0 kg/m2 | 289 | 1.0 | 1.20 | 1.01 | 0.86 | 1.19 (0.83 to 1.69) | 0.60 |
| ER+/PR+, BMI < 25.0 kg/m2 | 327 | 1.0 | 0.94 | 0.93 | 1.09 | 0.81 (0.56 to 1.17) | 0.43 |
| ER+/PR+, BMI ≥ 25.0 kg/m2 | 228 | 1.0 | 1.29 | 1.02 | 0.89 | 1.14 (0.76 to 1.71) | 0.81 |
BMI = body mass index; CI = confidence interval; ER = oestrogen receptor; PR = progesterone receptor; RR = relative risk. The multivariate model included the following: age at baseline (continuous), family history of breast cancer (any first or second degree relative; yes, no or unknown), history of benign breast disease (any benign breast disease prior to study baseline, including during the screening stages; yes or no), breast cancer screening history (women who had undergone a breast biopsy as part of the BCDDP screening but lacked evidence of malignant disease, women who were recommended for surgical consultation as part of the BCDDP but for whom the procedure was not performed, or women who represented a random sample of BCDDP participants who had no surgery or recommendation for surgical consultation during BCDDP screening), height (continuous), age at menarche (≤ 11, 12, 13 or 14+ years of age), age at menopause (age at which menstrual period stopped for at least three continuous months; <47 or 47+ years of age), age at first live birth (continuous), history of oral contraceptive use (yes or no), menopausal hormone therapy (ever or never), education attainment (less than or equal to high school or greater than high school), cigarette smoking (ever or never), and intakes of energy-adjusted dietary fat (continuous) and alcohol (continuous). Within each stratum, the group with lowest vigorous physical activity served as the reference group.